Question · asked by 1 review
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) vs ANY DOSE ‐ short term: Mental state: No clinically important improvement
- Population
- patients with schizophrenia
- Intervention
- STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day)
- Comparison
- ANY DOSE ‐ short term
- Outcome
- Mental state: No clinically important improvement
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) probably leads to lower mental state: 1. No clinically important improvement ‐ PANSS ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).
What each review found
Include earlier review versionsNo studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 4 · 100%High 0 · 0%
| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) vs ANY DOSE ‐ short term Mental state: 1. No clinically important improvement ‐ PANSS ‐ when compared with ultra low dose (<2 mg) · patients with schizophrenia STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) probably leads to lower mental state: 1. No clinically important improvement ‐ PANSS ‐ when… compared with ANY DOSE ‐ short term (moderate certainty). Risperidone dose for schizophrenia (2009) · Cochrane Headline outcomes only | RR 0.76 [0.6, 0.95] | 1 study · 459 participants | Moderate |
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) vs ANY DOSE ‐ short term Mental state: 1. No clinically important improvement ‐ PANSS ‐ when compared with low dose (greater than or equal to 2‐<4 mg/day) · patients with schizophrenia STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) probably leads to lower mental state: 1. No clinically important improvement ‐ PANSS ‐ when… compared with ANY DOSE ‐ short term (moderate certainty). Risperidone dose for schizophrenia (2009) · Cochrane Headline outcomes only | RR 0.66 [0.49, 0.9] | 3 studies · 196 participants | Moderate |
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) vs ANY DOSE ‐ short term Mental state: 1. No clinically important improvement ‐ PANSS ‐ when compared with standard‐lower dose (greater than or equal to 4‐<6 mg/day) · patients with schizophrenia STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) showed no clear difference in mental state: 1. No clinically important improvement ‐ PANSS ‐ when… compared with ANY DOSE ‐ short term (moderate certainty). Risperidone dose for schizophrenia (2009) · Cochrane Headline outcomes only | RR 0.94 [0.73, 1.2] | 1 study · 457 participants | Moderate |
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) vs ANY DOSE ‐ short term Mental state: 1. No clinically important improvement ‐ PANSS ‐ when compared with high dose (greater than or equal to 10 mg/day) · patients with schizophrenia STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) probably leads to lower mental state: 1. No clinically important improvement ‐ PANSS ‐ when… compared with ANY DOSE ‐ short term (moderate certainty). Risperidone dose for schizophrenia (2009) · Cochrane Headline outcomes only | RR 0.81 [0.68, 0.96] | 3 studies · 941 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.